DIATHERIS SA

Developing game-changing therapeutics for type 1 diabetes

Insulin therapy is the only option for type 1 diabetes (T1D) patients. Yet, this therapy is suboptimal. Central problem remains to achieve a proper glycemic control without the risk of life- threatening hypoglycemia and ketoacidosis. Diatheris is a spinoff from University of Geneva with the goal of developing a new therapeutic solution to overcome these limitations and improve T1D management. Diatheriss lead program consists in developing a proprietary game-changing approach based on a small protein called S100A9. S100A9 treatment is exploiting an insulin-independent pathway, which has shown remarkable results in combination with low-dose insulin, to improve glycemic control (normalizing glycemia) without the risk of hypoglycemia and ketoacidosis.

Only registered users have access to funding information.
Please log in or register to continue. Registration is free.

No news

17.10.2024

SA meeting at BfArM (Germany)

No Jobs

No videos and documents

Venture Kick

Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.

Venture Kick (50'000) 2023

Website